Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter?

@article{Spurio2013LowBA,
  title={Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter?},
  author={Federica Fasc{\`i} Spurio and Annalisa Aratari and Giovanna Margagnoni and Valeria Di Clemente and Alessandra Moretti and C Cortez Papi},
  journal={Journal of gastrointestinal and liver diseases : JGLD},
  year={2013},
  volume={22 1},
  pages={
          65-71
        }
}
Systemic corticosteroids have been used to treat active inflammatory bowel disease for over 50 years by virtue of their unquestionable efficacy in inducing clinical remission rapidly in the vast majority of patients. Nevertheless, traditional corticosteroids are associated to a plethora of potentially serious side effects due to their systemic metabolism; for this reason, interest has lately been growing in newer steroid compounds characterized by a high topical anti-inflammatory activity and a… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 59 REFERENCES

Efficacy and safety of beclomethasone dipropionate gastro-resistant, prolonged release tablets in mild to moderate ulcerative colitis: the Beta study

A Balzano, F Manguso, M Alberici
  • J Crohns Colitis
  • 2010
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL

Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine.

  • Journal of pediatric gastroenterology and nutrition
  • 2010
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Budesonide in the treatment of Crohn's disease: a meta-analysis.

  • Alimentary pharmacology & therapeutics
  • 2000
VIEW 16 EXCERPTS

European Crohn’s and Colitis Organisation (ECCO). e second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management

A Dignass, G Van Assche, JO Lindsay
  • J Crohns Colitis
  • 2010
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL